868707-84-0

Basic information

• Product Name: 1,4-Benzodioxin-6-carboxaldehyde, 2,3-dihydro-8-methyl-
• Synonyms: 1,4-Benzodioxin-6-carboxaldehyde, 2,3-dihydro-8-methyl-
• CAS NO: 868707-84-0
• Molecular Formula: C10H10O3
• Molecular Weight: 178.18
• Mol File: 868707-84-0.mol

Chemical Properties

• Boiling Point: 295.7±29.0 °C(Predicted)
• Appearance: /
• Density: 1.217±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1,4-Benzodioxin-6-carboxaldehyde, 2,3-dihydro-8-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Benzodioxin-6-carboxaldehyde, 2,3-dihydro-8-methyl-(868707-84-0)
• EPA Substance Registry System: 1,4-Benzodioxin-6-carboxaldehyde, 2,3-dihydro-8-methyl-(868707-84-0)

Safety Data

• Hazardous Substances Data: 868707-84-0(Hazardous Substances Data)

Upstream product

• 860003-88-9 3-bromo-4,5-ethylenedioxybenzaldehyde 
• 823-96-1 Trimethylboroxine 
• 594-27-4 tetramethylstannane 
• 868707-83-9 (8-methyl-2,3-dihydro-1,4-benzodioxin-6-yl)-methanol 

Relevant articles and documents

PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS

Tricyclic nitrogen containing compounds and their use as antibacterials. Z1and Z2 are independently selected from CH and N.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I), wherein A, X, Q, and R1 to R3 are defined as indicated in claim 1, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds, the use thereof, and methods for the production thereof.